In October 2017, Incyte entered into a global collaboration and license agreement with us in which they obtained exclusive worldwide rights for the development and commercialization of MGA012, an anti-PD-1 antibody, in all indications. In addition to receiving an upfront payment, MacroGenics is eligible to receive milestones and royalties and retains the right to develop its pipeline assets in combination with MGA012. Learn more
Collaborations have been a critical part of MacroGenics’ growth strategy and will continue to be an emphasis for our future growth strategy. To date, the company has developed significant alliances with leading pharmaceutical and biotechnology companies that enable us to drive forward our proprietary programs, while retaining significant value in the downstream potential of our partnered programs.
The company is actively exploring alliances that complement our expertise in biologics product development with important scientific, clinical and business capabilities. These alliances may incorporate our various technology platforms, product candidates and biologic product development capabilities.
MacroGenics’ Collaboration Partners
In September 2015, MacroGenics entered into a contract with the National Institute of Allergy and Infectious Diseases to perform product development and to advance DART product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with HIV infection (contract no. HHSN272201500032C). Learn more
In May 2016, Janssen entered into a collaboration agreement with us to develop and commercialize MGD015, a DART molecule designed to eliminate cells that overexpress an undisclosed antigen in various hematological malignancies and solid tumors.
MacroGenics retains co-promotion rights in the U.S. and may elect to fund a portion of late-stage clinical development to receive a profit share in the U.S. and Canada in lieu of royalties in these territories. Learn more
In October 2010, MacroGenics entered into a global research collaboration and license agreement with Pfizer to discover, develop and commercialize DART products directed at two undisclosed cancer targets. These DART proteins will be used to redirect the body’s cell-destroying, immune effector cells against tumor cells. Learn more
Under the terms of the September 2012 agreement, MacroGenics retains full development and commercialization rights to three oncology DART molecules in North America, Japan, Korea and India, while Servier has an option to obtain an exclusive license covering the rest of the world. Servier has exercised this option with respect to MGD006 and still retains its options with respect to MGD007 and one other program. Learn more
In July 2010, Green Cross entered into a collaboration agreement with MacroGenics for the development and exclusive commercialization of margetuximab in South Korea.
Boehringer Ingelheim entered into a global alliance to discover, develop and commercialize antibody-based therapeutics which may span multiple therapeutic areas. These drug candidates will be based on our DART platform and will be directed against up to ten combinations of molecular targets. Learn more
In January 2018, we announced that Roche entered into a research collaboration and license agreement with us to jointly discover and develop novel bispecific molecules to undisclosed targets. In addition to receiving an upfront payment, MacroGenics is eligible to receive milestones and royalties on future sales. Learn more